The WIC-APAC External Advisory Board comprises international friends and experts who share a strong commitment to advancing cancer immunology and immunotherapy in the Asia-Pacific region. While not based within the region, Advisory Board members provide strategic perspectives and support WIC-APAC’s mission through periodic consultation and engagement across WIC-APAC meetings and satellite events.
John Connolly, PhD, is Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy (PICI), leading its research strategy. A human immunologist, he also supports translational immunology and cell therapy initiatives in Singapore.
Dr. Daniel Powell Jr. is Professor of Pathology and Laboratory Medicine and Scientific Director of Immunotherapy in Gynecologic Oncology at the University of Pennsylvania. His work focuses on translational immunotherapy for solid tumours, including adoptive T cell therapies and next-generation CAR/TIL strategies.
Bernard A. Fox, PhD, is the Harder Family Chair for Cancer Research and Chief of the Laboratory of Molecular and Tumor Immunology at the Earle A. Chiles Research Institute (Providence Cancer Institute). He is Founder and CEO of UbiVac and chairs the World Immunotherapy Council (since 2012).
Prof. Sergio Quezada is Professor of Cancer Immunology and Immunotherapy at University College London (UCL), focusing on regulatory T cells, the tumour microenvironment, and immune checkpoint blockade. He contributed to founding Achilles Therapeutics and served as its Chief Scientific Officer (2020–2025).
Michael T. Lotze, MD, is Professor of Surgery, Immunology, and Bioengineering and Director of the DAMP Laboratories at UPMC Hillman Cancer Center. A clinician-scientist in cancer immunotherapy and cell/gene therapy, he is Editor-in-Chief of the Journal for Immunotherapy of Cancer.